Wells Fargo increased its price target on
Amgen (AMGN) from $375 to $390. Amgen's drug
Repatha has been found to significantly reduce heart risk in diabetes patients. Analysts are advising vigilance with regard to
Amgen's share valuation due to inconsistent short- and long-term returns. Multiple financial institutions, including
Czech National Bank and
National Wealth Management Group, purchased significant numbers of Amgen shares, while others sold off their holdings. The
Vanguard Group reported zero holdings following internal realignment.
Piper Sandler lifted its price target on Amgen to $342. Notably, a recent increase in Amgen's share price did not affect its market performance. Amgen's
obesity strategy is expanding due to collaboration with Ro on GLP-1 therapies. The
European Commission approved Amgen's Uplizna for generalized Myasthenia Gravis. Amgen announced a second quarter
dividend for 2026, while
CEO Bradway reported a significant share tax-withholding transaction. The company also demonstrated commitment to cost-effectiveness of medicines for US patients.
Amgen AMGN News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 28 Mar 2026 20:45:04 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -3
